Taikang Asset Management Hong Kong Co Ltd Has $10.49 Million Stake in IQVIA Holdings Inc. $IQV

Taikang Asset Management Hong Kong Co Ltd raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,543 shares of the medical research company’s stock after purchasing an additional 4,817 shares during the quarter. IQVIA accounts for 1.0% of Taikang Asset Management Hong Kong Co Ltd’s investment portfolio, making the stock its 26th biggest holding. Taikang Asset Management Hong Kong Co Ltd’s holdings in IQVIA were worth $10,491,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Ameliora Wealth Management Ltd. purchased a new position in IQVIA during the 4th quarter valued at about $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC acquired a new position in shares of IQVIA in the fourth quarter worth $27,000. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA during the third quarter valued at $30,000. Finally, Activest Wealth Management increased its position in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.4%

Shares of NYSE:IQV opened at $179.04 on Wednesday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock’s 50-day moving average is $173.77 and its 200-day moving average is $192.69. The company has a market cap of $29.88 billion, a P/E ratio of 22.19, a P/E/G ratio of 1.53 and a beta of 1.21. IQVIA Holdings Inc. has a 52-week low of $153.01 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts recently commented on IQV shares. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the company from $174.00 to $213.00 in a research note on Monday, March 9th. HSBC set a $210.00 price target on shares of IQVIA in a research note on Wednesday, June 3rd. Morgan Stanley set a $225.00 target price on IQVIA in a report on Thursday, May 7th. Evercore reissued an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Finally, Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research report on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.